# DEA Marijuana Rescheduling Hearings Near Conclusion > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-marijuana-rescheduling-hearings-near-conclusion/ > **Published:** 2026-07-30T12:16:21-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:09-04:00 > **Clinical Summary:** How DEA cannabis rescheduling to Schedule III will reshape medical practice, research access, and clinical documentation for physicians. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustrySafetyPainAnxietyMental Health Why This Matters Rescheduling marijuana from Schedule I to Schedule III would dramatically expand the volume and types of [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) clinicians can access, potentially providing the robust evidence base currently lacking for [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). The tax code changes associated with rescheduling would lower costs for patients and medical institutions by allowing standard business deductions, improving medication affordability and accessibility. Clinicians need to track this regulatory decision closely because it will determine whether they can prescribe cannabis products with FDA oversight and whether their patients will have legally protected access to standardized, regulated formulations. Clinical Summary The DEA’s ongoing rescheduling hearings are nearing conclusion and will determine whether cannabis moves from Schedule I to Schedule III controlled substance status, a change with substantial implications for clinical practice and research. Rescheduling to Schedule III would dramatically expand research accessibility by reducing regulatory barriers that currently limit cannabis studies, potentially accelerating evidence generation on efficacy and safety across therapeutic applications. This regulatory shift would also affect the [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) industry through tax code changes, as Schedule III substances are not subject to the same prohibitive IRC Section 280E tax provisions that currently prevent cannabis businesses from deducting ordinary operating expenses, which could increase product affordability and accessibility for patients. Additionally, rescheduling would align federal law more closely with the growing number of state-level [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) programs, reducing the legal ambiguity that currently complicates clinical decision-making and patient access. Clinicians should monitor the outcome of these hearings as it will directly influence their ability to recommend [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/), refer patients to regulated dispensaries with greater confidence, and participate in prospective [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) without the current federal constraints. Regardless of the rescheduling decision, physicians should prepare for potential changes by staying informed about [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/), drug interactions, and evolving legal frameworks in their respective states. Dr. Caplan’s Take “What we’re seeing with the DEA process is an opportunity to align our [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) with the actual evidence we’ve accumulated over the past two decades, though I’d caution that rescheduling alone won’t resolve the fundamental gap between what we observe clinically and what we still need to understand through rigorous, federally-supported research.” Clinical Perspective 💊 The impending DEA rescheduling decision represents a potential watershed moment for cannabis in clinical medicine, though providers should recognize that administrative reclassification alone does not resolve fundamental evidence gaps about efficacy, dosing, drug interactions, or long-term safety profiles for most indications. Rescheduling from Schedule I to Schedule III would theoretically facilitate research and reduce certain tax burdens on state-legal cannabis businesses, yet the actual clinical utility will depend heavily on the quality and rigor of studies that follow, as well as continued regulatory frameworks governing product standardization and labeling. Clinicians should remain cautious about extrapolating perceived legitimacy from scheduling changes to clinical endorsement, since DEA decisions are primarily administrative and do not substitute for robust clinical trial data or consensus guidelines. In the interim, providers managing patients who use or are considering cannabis should continue documenting use patterns, monitoring for adverse effects and drug interactions, and discussing the current evidence 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20DEA%20Marijuana%20Rescheduling%20Hearings%20Near%20Conclusion%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71763)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71763)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20DEA%20Marijuana%20Rescheduling%20Hearings%20Near%20Conclusion%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71763)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [MMJ The Voice DEA Didn’t Want to Hear From During Marijuana Rescheduling Hearings](https://cedclinic.com/mmj-the-voice-dea-didnt-want-to-hear-from-during-marijuana-rescheduling-hearings/) 📰 Source: [https://thefreshtoast.com/culture/dea-marijuana-rescheduling-hearings-near-conclusion/](https://thefreshtoast.com/culture/dea-marijuana-rescheduling-hearings-near-conclusion/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).